79. Homozygous familial hypercholesterolemia
128 clinical trials,   105 drugs   (DrugBank: 29 drugs),   8 drug target genes,   15 drug target pathways
Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2005-003626-26-GB (EUCTR) | 14/06/2006 | 01/11/2005 | A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous familial hypercholesterolemia | A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous familial hypercholesterolemia | Treatment of primary dyslipidemia MedDRA version: 8;Level: PT;Classification code 10058108 | Product Name: TAK-475 Product Code: TAK-475 | Takeda Europe R&D Centre Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | United Kingdom | |||
2 | NCT00263081 (ClinicalTrials.gov) | November 2005 | 6/12/2005 | Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia | A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Co-administered With Current Lipid-lowering Therapy in Subjects With Homozygous Familial Hypercholesterolemia. | Hypercholesterolemia | Drug: Lapaquistat acetate and current lipid-lowering treatment;Drug: Current lipid-lowering treatment | Takeda | NULL | Terminated | 8 Years | N/A | Both | 44 | Phase 3 | United States;Canada;France;Israel;Poland;United Kingdom |